Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Pediatric Rheumatology

The Long-Term Outlook: Monitoring and School Success

At a Glance

Juvenile dermatomyositis may settle after one episode or return in relapses, so follow-up is individualized rather than automatic. Care teams monitor hidden lung or heart problems, calcium lumps, steroid effects on bones and growth, and school needs.

As your child’s Juvenile Dermatomyositis (JDM) stabilizes, the focus of care shifts from controlling acute inflammation to managing the long-term health of their body. JDM may follow a monophasic course (one episode followed by lasting remission) or a relapsing course; not every child enters a permanent “chronic” phase [1][2].

The long-term outlook depends on disease control, complications, and treatment response. This involves careful, individualized monitoring for complications that can sometimes develop even when the disease seems quiet.

Surveillance for “Silent” Organ Involvement

Because inflammation can affect the lungs and heart without causing obvious symptoms like a cough or chest pain, specialists recommend proactive monitoring. There is no single universal schedule for all patients; screening is risk-based and clinician-directed [2][3].

Pulmonary (Lung) Health

Lungs can become scarred or inflamed, a condition known as Interstitial Lung Disease (ILD) [2].

  • Screening: Doctors use baseline and repeat Pulmonary Function Tests (PFTs) to measure lung volume and oxygen transfer (DLCO) if the child is old enough to cooperate with the testing [2][4].
  • Imaging: A High-Resolution CT (HRCT) scan looks for fine details of lung tissue. Because it involves radiation, HRCT is reserved for children with concerning respiratory symptoms, abnormal physical exams, changes in PFTs, or specialist judgment—not used as an automatic schedule solely because of an antibody [5][6].

Cardiac (Heart) Health

While uncommon, JDM can cause subtle changes in heart muscle function or electrical rhythms [7][8].

  • Checks: Some clinicians obtain a baseline Electrocardiogram (ECG) and an Echocardiogram (ultrasound of the heart). Follow-up testing is repeated when symptoms, severe disease, or prior abnormalities justify it [7].
  • Advanced Imaging: Tests like speckle-tracking or Cardiac MRI are specialized tools used in selected cases to detect subclinical dysfunction, rather than routine care for every child [9][3].

Managing Calcinosis

Calcinosis is the formation of hard calcium lumps in the skin or muscles [10]. Prevalence varies substantially by cohort and disease duration. It is often linked to a longer period of untreated disease or the presence of the anti-NXP2 antibody [11][12].

  • Prevention: The best defense against calcinosis is early, aggressive treatment to stop the initial inflammation, though this reduces risk without guaranteeing prevention [11][13].
  • Monitoring: Doctors typically use physical examination, plain radiographs (X-rays), or ultrasound. CT scans are selective due to radiation [14][15].
  • Treatment: Treatment is highly individualized and evidence is often limited. Options may include pain and skin care, physical therapy, or medications (like IVIG or calcium-metabolism drugs) in certain cases [16][17].

The Impact of Long-Term Steroid Use

While steroids are life-saving in JDM, cumulative exposure requires careful management [1][18].

  • Bone Health: Steroids can reduce bone density. Children may receive DXA scans (a specialized bone density X-ray), ordered based on cumulative steroid exposure, fracture history, and other risk factors rather than an automatic schedule [18][19].
  • Growth and Puberty: Chronic steroid use can slow down a child’s growth speed or delay the onset of puberty [1]. Your rheumatologist will track height and weight at every visit.
  • Metabolic Changes: Typical steroid effects include increased appetite, high blood pressure, elevated blood sugar, mood changes, truncal weight gain, and cushingoid facial rounding. (Note: True lipodystrophy—the severe loss of fat in the limbs—is an uncommon condition that may be related to JDM itself rather than routine steroid use, and requires separate evaluation) [20][21].

Success in School

Your child’s medical team should provide documentation to help the school accommodate the unique needs of JDM. In the United States, common supports are written into a 504 Plan or IEP (equivalent support systems exist in other countries) [22][23]:

  • UV Protection: Policies allowing hats/long sleeves and self-applied sunscreen, as school sunscreen policies vary and must be documented [22].
  • Physical Activity: Adapted PE that allows for rest breaks or modified exercises based on current strength levels [19][24].
  • Energy Management: Permission to use an elevator, a second set of books for home, and extra time between classes [23].
  • Medical Needs: A clear plan for safe medication storage, and instructions for school nurses on when to call parents [25].

Common questions in this guide

Can JDM go away, or does it always become chronic?
JDM does not follow the same course in every child. It may occur as one episode followed by lasting remission, or it may return in relapses; the long-term outlook depends on disease control, complications, and treatment response.
What tests check for hidden lung or heart problems in a child with JDM?
Lung monitoring may use pulmonary function tests to measure breathing and oxygen transfer when a child can cooperate. Heart monitoring may include an electrocardiogram (ECG) and echocardiogram; repeat testing or specialized scans are chosen based on symptoms, disease severity, prior findings, and specialist judgment rather than one schedule for everyone.
How can we watch for or reduce calcinosis in JDM?
Calcinosis is the development of hard calcium deposits in the skin or muscles. Early treatment of JDM inflammation may lower the risk, while clinicians monitor for deposits with examination and sometimes X-rays or ultrasound; treatment can include pain and skin care, physical therapy, IVIG, or calcium-related medicines in selected cases.
What should families monitor when a child takes steroids for JDM?
Long-term steroid exposure can affect bone density, growth, puberty, appetite, blood pressure, blood sugar, mood, and body weight. The rheumatology team tracks height and weight and may order a DXA bone-density scan based on steroid exposure, fracture history, and other risks.
What school accommodations can help a student with JDM?
A 504 Plan, IEP, or similar school plan can document sun protection, self-applied sunscreen, adapted physical education, rest breaks, elevator access, extra time between classes, and medication procedures. The medical team can provide a letter explaining the child’s current needs and when the school should contact the family.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my child's anti-NXP2 status and current nailfold capillary health, how high is their risk for developing calcinosis?
  2. 2.Since cardiac and lung involvement can be 'silent,' what is our specific schedule for repeat PFTs, EKGs, and echocardiograms over the next two years?
  3. 3.When should we schedule the next DXA scan to monitor for the impact of long-term steroids on bone density?
  4. 4.Are you seeing any changes in my child's growth curve or fat distribution that might indicate early lipodystrophy or metabolic issues?
  5. 5.Can you provide a letter for the school that specifically details the need for indoor PE options and the ability to self-apply sunscreen during the day?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Impact of Juvenile Dermatomyositis on Growth, Puberty, Bone Mineral Density, and Body Composition in Children.

    Sudhera N, Kaur H, Pandiarajan V, Singh S

    Mediterranean journal of rheumatology 2026; (37(1)):136-145 doi:10.31138/mjr.280725.ran.

    PMID: 42100059
  2. 2

    Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium to Longstanding Juvenile Dermatomyositis.

    Barth Z, Schwartz T, Flatø B, et al.

    Arthritis care & research 2019; (71(4)):492-497 doi:10.1002/acr.23687.

    PMID: 29953739
  3. 3

    Cardiac evaluation of patients with juvenile dermatomyositis.

    Akgün G, Sözeri B, Başar EZ, et al.

    Pediatric research 2025; (97(1)):333-340 doi:10.1038/s41390-024-03336-8.

    PMID: 38909159
  4. 4

    Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement.

    Berntsen KS, Tollisen A, Schwartz T, et al.

    The Journal of rheumatology 2017; (44(6)):827-834 doi:10.3899/jrheum.160997.

    PMID: 28365577
  5. 5

    Profile of patients with Juvenile Dermatomyositis and Anti-MDA5 autoantibodies.

    Vignesh P, Nadig PL, Basu S, et al.

    Pediatric research 2025; (97(6)):2020-2028 doi:10.1038/s41390-024-03551-3.

    PMID: 39313554
  6. 6

    Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling.

    Melki I, Devilliers H, Gitiaux C, et al.

    Rheumatology (Oxford, England) 2020; (59(8)):1927-1937 doi:10.1093/rheumatology/kez525.

    PMID: 31755959
  7. 7

    Cardiac findings in children with juvenile Dermatomyositis at disease presentation.

    Cantez S, Gross GJ, MacLusky I, Feldman BM

    Pediatric rheumatology online journal 2017; (15(1)):54 doi:10.1186/s12969-017-0182-0.

    PMID: 28693511
  8. 8

    Juvenile dermatomyositis presenting as complete heart block in a 10-year-old girl.

    Ghosh R, Roy D, Dubey S, et al.

    Paediatrics and international child health 2020; (40(4)):251-254 doi:10.1080/20469047.2020.1765123.

    PMID: 32427522
  9. 9

    Echocardiographic study of juvenile dermatomyositis patients: new insights from speckle-tracking-derived strain.

    Diniz MFR, Kozu KT, Elias AM, et al.

    Clinical rheumatology 2021; (40(4)):1497-1505 doi:10.1007/s10067-020-05418-4.

    PMID: 32989504
  10. 10

    The Vasculopathy of Juvenile Dermatomyositis.

    Papadopoulou C, McCann LJ

    Frontiers in pediatrics 2018; (6()):284 doi:10.3389/fped.2018.00284.

    PMID: 30356795
  11. 11

    Skin disease is more recalcitrant than muscle disease: A long-term prospective study of 184 children with juvenile dermatomyositis.

    Wang A, Morgan GA, Paller AS, Pachman LM

    Journal of the American Academy of Dermatology 2021; (84(6)):1610-1618 doi:10.1016/j.jaad.2020.12.032.

    PMID: 33359787
  12. 12

    Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series.

    Toplak N, Pimpale Chavan P, Rosina S, et al.

    Frontiers in pediatrics 2021; (9()):810785 doi:10.3389/fped.2021.810785.

    PMID: 35280444
  13. 13

    Early Abnormal Nailfold Capillary Changes Are Predictive of Calcinosis Development in Juvenile Dermatomyositis.

    Nozawa T, Bell-Peter A, Marcuz JA, et al.

    The Journal of rheumatology 2022; (49(11)):1250-1255 doi:10.3899/jrheum.220249.

    PMID: 35914785
  14. 14

    Development of a computed tomography calcium scoring technique for assessing calcinosis distribution, pattern and burden in dermatomyositis.

    Cervantes BA, Gowda P, Rider LG, et al.

    Rheumatology (Oxford, England) 2024; (63(1)):58-63 doi:10.1093/rheumatology/kead256.

    PMID: 37286372
  15. 15

    Use of the EOS 2D/3D Imaging System for the Evaluation of Calcinosis in Juvenile Dermatomyositis: A Retrospective Case Series.

    Maguire CA, Lawrence CN, Lala SV, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2026; doi:10.1097/RHU.0000000000002342.

    PMID: 41973030
  16. 16

    Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis.

    Yi BY, Wahezi DM, Covert L, et al.

    Clinical and experimental rheumatology 2026; (44(2)):390-397 doi:10.55563/clinexprheumatol/35pbbq.

    PMID: 40737048
  17. 17

    Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature.

    Traineau H, Aggarwal R, Monfort JB, et al.

    Journal of the American Academy of Dermatology 2020; (82(2)):317-325 doi:10.1016/j.jaad.2019.07.006.

    PMID: 31302187
  18. 18

    Bone mineral density and explanatory factors in children and adults with juvenile dermatomyositis at long term follow-up; a cross sectional study.

    Marstein HS, Godang K, Flatø B, et al.

    Pediatric rheumatology online journal 2021; (19(1)):56 doi:10.1186/s12969-021-00543-z.

    PMID: 33902632
  19. 19

    Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

    Zhang Y, Milojevic D

    Paediatric drugs 2017; (19(3)):193-211 doi:10.1007/s40272-017-0219-3.

    PMID: 28290112
  20. 20

    Long-term outcome of juvenile dermatomyositis associated with lipodystrophy: experience of a University hospital.

    Kapetanović I, Gajić-Veljić M, Bonači-Nikolić B, Nikolić M

    Anais brasileiros de dermatologia 2025; (100(4)):501130 doi:10.1016/j.abd.2025.501130.

    PMID: 40554351
  21. 21

    Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis.

    Sahinoz M, Khairi S, Cuttitta A, et al.

    Clinical diabetes and endocrinology 2018; (4()):6 doi:10.1186/s40842-018-0058-3.

    PMID: 29610677
  22. 22

    Promising Treatments in Juvenile Dermatomyositis.

    Yi BY, Joyce M, Gilbert R, Kim S

    Rheumatic diseases clinics of North America 2025; (51(4)):719-735 doi:10.1016/j.rdc.2025.07.012.

    PMID: 41161909
  23. 23

    A multicentre study for clinical phenotype prediction in juvenile dermatomyositis: categorical principal component analysis-based hierarchical clustering.

    Torun R, Cüceoğlu MK, Arslanoğlu Aydın E, et al.

    Reumatologia 2026; (64(2)):83-93 doi:10.5114/reum/209913.

    PMID: 42306292
  24. 24

    Idiopathic Inflammatory Myopathies.

    Balan S, Madan S

    Indian journal of pediatrics 2024; (91(10)):1041-1048 doi:10.1007/s12098-023-04896-z.

    PMID: 37919486
  25. 25

    Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.

    He L

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2021; (23(10)):1064-1068 doi:10.7499/j.issn.1008-8830.2106011.

    PMID: 34719424

This page explains long-term monitoring and school support for children with juvenile dermatomyositis for informational purposes only and does not replace medical advice. Your child’s pediatric rheumatology team should set testing schedules and interpret symptoms, treatments, and school needs.

Get notified when new evidence is published on Juvenile dermatomyositis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.